Amphastar Pharmaceuticals AMPH Ratios & Valuation
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | 47.3%-2.1pp | 49.5%+0.1pp | 49.4%-0.5pp | 49.9%-0.6pp | 50.5%-0.6pp | |
| Operating margin | 16.2%-3.3pp | 19.5%-1.2pp | 20.7%-4.4pp | 25.1%-1.5pp | 26.6%-1.4pp | |
| Net margin | 11%-2.6pp | 13.6%-1.8pp | 15.4%-3.2pp | 18.6%-0.7pp | 19.4%-2.4pp | |
| EBITDA margin | 24.2%-3.2pp | 27.4%-1.1pp | 28.4%-4.3pp | 32.8%-1.2pp | 34%-1.3pp | |
| Free cash flow margin | 18.8%+1.9pp | 16.8%+1.2pp | 15.7%+0.1pp | 15.5%-5.0pp | 20.6%-3.0pp | |
| Returns | ||||||
| Return on assets | 4.8%-1.3pp | 6.1%-0.8pp | 7%-1.7pp | 8.7%-0.2pp | 8.9%-1.5pp | |
| Efficiency | ||||||
| Asset turnover | 0.4×0.0× | 0.4×0.0× | 0.5×0.0× | 0.5×0.0× | 0.5×0.0× | |
| Inventory turnover | 2.1×-0.1× | 2.2×-0.1× | 2.3×0.0× | 2.3×-0.1× | 2.4×-0.4× | |
| Liquidity | ||||||
| Current ratio | 3.9×-0.2× | 4×+0.9× | 3.1×-0.2× | 3.3×+0.3× | 3×-0.1× | |
| Quick ratio | 2.8×-0.1× | 2.9×+0.7× | 2.2×0.0× | 2.2×+0.2× | 2×-0.2× | |
| Cash ratio | 1×0.0× | 1.1×0.0× | 1.1×0.0× | 1.1×+0.1× | 0.9×0.0× | |
| Leverage | ||||||
| Debt-to-assets | 0.4×0.0× | 0.4×0.0× | 0.4×0.0× | 0.4×0.0× | 0.4×0.0× | |
| Net debt / EBITDA | 3×+0.5× | 2.5×+0.3× | 2.1×+0.2× | 2×+0.1× | 1.9×0.0× | |
| Interest coverage | 4.5×-1.0× | 5.5×-0.4× | 5.9×-1.1× | 7.1×+0.1× | 6.9×+0.2× | |
| Valuation | ||||||
| Market capitalization | $927.72M-19.9% | $1.23B-0.7% | $1.24B+6.9% | $1.16B-16.1% | $1.38B-22.6% | |
| Enterprise value | $1.44B-11.3% | $1.72B+2.2% | $1.68B+3.3% | $1.63B-12.1% | $1.85B-19.0% | |
| Price / earnings | 11.7×+3.5× | 12.5×+1.4× | 11.1×+2.5× | 8.6×-1.2× | 9.8×-1.4× | |
| Price / sales | 1.3×-0.3× | 1.7×0.0× | 1.7×+0.1× | 1.6×-0.3× | 1.9×-0.5× | |
| EV / EBITDA | 8.3×+1.7× | 8.7×+0.5× | 8.2×+1.3× | 6.9×-0.6× | 7.5×-1.4× | |
| EV / sales | 2×-0.2× | 2.4×+0.1× | 2.3×+0.1× | 2.3×-0.3× | 2.5×-0.6× | |
| Free cash flow yield | 14.6%+1.6pp | 9.9%+0.7pp | 9.1%-0.5pp | 9.7%-1.2pp | 10.9%+1.2pp | |
| Earnings yield | 8.5%-3.7pp | 8%-1.0pp | 9%-2.6pp | 11.6%+1.4pp | 10.3%+1.3pp |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Amphastar Pharmaceuticals's profit margins?
- Amphastar Pharmaceuticals (AMPH) runs a 47.3% gross margin and a 16.2% operating margin, with a 11.0% net margin.
- Where do Amphastar Pharmaceuticals's ratios come from?
- Every ratio is computed from Amphastar Pharmaceuticals's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
